Harlan CRS and Bertin Pharma sign strategic collaboration deal

5 March 2014

Harlan Contract Research Services a division of Harlan Laboratories and France’s Bertin Pharma have entered announced a strategic partnership to offer a comprehensive package for early drug development.

Under the agreement, the companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies. Through the alliance, Harlan CRS will strengthen its drug discovery and translational medicine offerings utilizing Bertin Pharma's expertise in immunology and biomarkers.

"We welcome this strategic agreement with Bertin Pharma. Its expertise in the immunological sector is impressive and well-known in the industry," said Manuela Leone, president of Harlan CRS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >